Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Drug Metab Dispos ; 40(9): 1834-45, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22711749

RESUMO

Negative allosteric modulation (NAM) of metabotropic glutamate receptor subtype 5 (mGlu5) represents a therapeutic strategy for the treatment of childhood developmental disorders, such as fragile X syndrome and autism. VU0409106 emerged as a lead compound within a biaryl ether series, displaying potent and selective inhibition of mGlu5. Despite its high clearance and short half-life, VU0409106 demonstrated efficacy in rodent models of anxiety after extravascular administration. However, lack of a consistent correlation in rat between in vitro hepatic clearance and in vivo plasma clearance for the biaryl ether series prompted an investigation into the biotransformation of VU0409106 using hepatic subcellular fractions. An in vitro appraisal in rat, monkey, and human liver S9 fractions indicated that the principal pathway was NADPH-independent oxidation to metabolite M1 (+16 Da). Both raloxifene (aldehyde oxidase inhibitor) and allopurinol (xanthine oxidase inhibitor) attenuated the formation of M1, thus implicating the contribution of both molybdenum hydroxylases in the biotransformation of VU0409106. The use of ¹8O-labeled water in the S9 experiments confirmed the hydroxylase mechanism proposed, because ¹8O was incorporated into M1 (+18 Da) as well as in a secondary metabolite (M2; +36 Da), the formation of which was exclusively xanthine oxidase-mediated. This unusual dual and sequential hydroxylase metabolism was confirmed in liver S9 and hepatocytes of multiple species and correlated with in vivo data because M1 and M2 were the principal metabolites detected in rats administered VU0409106. An in vitro-in vivo correlation of predicted hepatic and plasma clearance was subsequently established for VU0409106 in rats and nonhuman primates.


Assuntos
Aldeído Oxidase/metabolismo , Benzamidas/farmacocinética , Antagonistas de Aminoácidos Excitatórios/farmacocinética , Fígado/enzimologia , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Tiazóis/farmacocinética , Xantina Oxidase/metabolismo , Aldeído Oxidase/antagonistas & inibidores , Alopurinol/farmacologia , Animais , Benzamidas/administração & dosagem , Benzamidas/sangue , Benzamidas/química , Biotransformação , Cromatografia Líquida , Inibidores Enzimáticos/farmacologia , Antagonistas de Aminoácidos Excitatórios/administração & dosagem , Antagonistas de Aminoácidos Excitatórios/sangue , Antagonistas de Aminoácidos Excitatórios/química , Hepatócitos/enzimologia , Humanos , Hidroxilação , Injeções Intravenosas , Fígado/efeitos dos fármacos , Macaca fascicularis , Espectroscopia de Ressonância Magnética , Masculino , Taxa de Depuração Metabólica , Microssomos Hepáticos/enzimologia , Modelos Biológicos , Estrutura Molecular , Isótopos de Oxigênio , Cloridrato de Raloxifeno/farmacologia , Ratos , Ratos Sprague-Dawley , Receptor de Glutamato Metabotrópico 5 , Especificidade da Espécie , Espectrometria de Massas em Tandem , Tiazóis/administração & dosagem , Tiazóis/sangue , Tiazóis/química , Xantina Oxidase/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...